We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Bio-Rad Honored With Awards

By Biotechdaily staff writers
Posted on 28 Oct 2005
Bio-Rad Laboratories, Inc. More...
(Hercules, CA, USA) has received a Market Leadership Award for drug discovery technologies for the company's KnowItAll ADME (absorption, digestion, metabolism, excretion)/Tox software and databases. The award, from the international consulting firm Frost & Sullivan (Palo Alto, CA, USA), is given to a single company annually that has displayed excellence in all areas of market leadership, including the identification of market challenges, drivers and restraints, as well as strategy development and methods of addressing these market dynamics.

"The company is recognized for excelling in market share, revenue growth rates, and profitability, as well as market and technology innovation,” explained Dr. Amarpreet Dhiman, industry analyst with Frost & Sullivan. "A clear understanding of end-user needs, a commitment to providing outstanding customer service, and the ability to forge productive collaborations have powered the constant expansion of the award recipient's client base.”

Bio-Rad's KnowItAll informatics system for in silico ADME/Tox offers a complete suite of tools for the computer-based prediction of a potential drug's ADME/Tox profile, including one of the largest collections of predictive models, applications to build and validate predictive models, experimental ADME/Tox data, and integrated tools for chemical structure handling, data management, and reporting.

Bio-Rad also received a Product Innovation Award from Frost & Sullivan for ADME/Tox Informatics. Winners are selected on the basis of market participant interviews, end-user surveys, and secondary research. The recipient must also demonstrate innovation by launching a broad line of emerging products and technologies.




Related Links:
Bio-Rad

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.